Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
← catalyst calendarNCT07607327 · readout in 1,230 d
Sponsored by CareDx (industry) · CDNA — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
400estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-31 | estimated | When the study began enrolling |
| Primary completion | 2029-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- AML (Acute Myelogenous Leukemia)
- MDS (Myelodysplastic Syndrome)
- CMML
Intervention
- Diagnostic test: AlloHeme
Primary outcome
what the primary-completion date above is the date OFTo evaluate AlloHeme test performance in predicting post-transplant relapse (by FDA criteria) or any cytogenetic/molecular evidence of disease resulting in unplanned treatment intervention in AML and MDS patients.
measured 12 months
Permalink · CDNA's whole pipeline · Catalyst calendar · Every registered study · What changed